
Germany · Health startup
DasLab is a German healthtech company founded in 2020, focused on creating a vendor-neutral digital platform that integrates medical diagnostic testing with telemedicine and health
Funding reportedLast round: Seed
DasLab is a German healthtech company founded in 2020, focused on creating a vendor-neutral digital platform that integrates medical diagnostic testing with telemedicine and health
care delivery systems. This platform enables seamless at-home and point-of-care diagnostics in Germany and Spain. The company aims to enhance the digital health ecosystem by promoting effective, efficient, and personalized healthcare through data interoperability. DasLab offers a digital diagnostics infrastructure that includes a Diagnostics API for integrating lab data into digital patient records. Patients can book tests that are conducted at home or through partner providers, with samples sent to partner laboratories. The company also supports lab workflow automation and provides innovative prevention programs for cancer and chronic diseases. With a team of approximately 31 employees, DasLab connects various stakeholders in the healthcare ecosystem, including healthcare providers, diagnostic laboratories, logistics providers, health insurers, and telemedicine platforms.
Funding, as reported
From DasLab's own website: 2 founders.
What they build
Known for
health careinteroperable diagnosticsdigital healthcloud-based healthcare softwareconsumerslaboratory data managementpreventive healthcarecomputer & network securityremote diagnosticseu digital healthapi-first platformearly detection programspreventive screeninginformation technology & servicesdigital health transformationdigital colorectal cancer screening
Built with from their website
Amazon SESGoogle Tag ManagerLiteSpeedWordPress.orgHREF LangAtlassianPWAElementorGoogle WorkspaceCloudFlare
Viewport MetaGoogle DriveSite KitwebpackBabelApple Business ManagerGoogle MeetCloudFlare CDN
Add your raise, your deck and your story, and put DasLab in front of investors. Or tell us what we have wrong.